Literature DB >> 26851751

Cancer among patients with type 2 diabetes mellitus: A population-based cohort study in northeastern Italy.

Andrea Gini1, Ettore Bidoli2, Loris Zanier3, Elena Clagnan3, Giorgio Zanette4, Michele Gobbato3, Paolo De Paoli5, Diego Serraino2.   

Abstract

Diabetes mellitus (DM) is associated with an elevated risk of cancer. The aim of this study was to assess cancer risk and survival in individuals with type 2 DM (T2DM) in Friuli Venezia Giulia, Italy. A retrospective population-based cohort study of 32,247 T2DM patients aged 40-84 years was conducted through a record linkage of local healthcare databases and cancer registry for the period 2002-2009. Standardized incidence ratios (SIRs) with 95% confidence intervals (95%CIs) and 5-year survival probabilities after T2DM and cancer diagnosis were computed. The SIRs for all cancers (n=2069) was 1.28 (95%CI: 1.23-1.34). The highest SIRs were observed for cancers of the liver, female genital organs, small intestine, and pancreas. After 3 years from T2DM diagnosis, a reduced risk of prostate cancer (SIR=0.73, 95%CI: 0.54-0.96) was found in men aged 65-74 years, and a higher risk for breast cancer (SIR=1.24, 95%CI: 1.00-1.52) was found among T2DM female patients. The overall 5-year survival after T2DM was 88.7%. Furthermore, T2DM appeared to have a negative effect on survival of women with breast cancer. This population-based study confirmed that T2DM patients are at increased risk of several cancers, and of premature death in women with breast cancer.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Cancer risk; Population-based cohort study; Record linkage; Survival; Type 2 diabetes mellitus

Mesh:

Year:  2016        PMID: 26851751     DOI: 10.1016/j.canep.2016.01.011

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  8 in total

1.  Systems and precision medicine approaches to diabetes heterogeneity: a Big Data perspective.

Authors:  Enrico Capobianco
Journal:  Clin Transl Med       Date:  2017-07-25

2.  Diabetes mellitus and the risk of gastrointestinal cancer in women compared with men: a meta-analysis of cohort studies.

Authors:  Hong-Juan Fang; Shao-Bo Shan; Yu-Hao Zhou; Li-Yong Zhong
Journal:  BMC Cancer       Date:  2018-04-16       Impact factor: 4.430

3.  Sex differences in the association between diabetes and cancer: a systematic review and meta-analysis of 121 cohorts including 20 million individuals and one million events.

Authors:  Toshiaki Ohkuma; Sanne A E Peters; Mark Woodward
Journal:  Diabetologia       Date:  2018-07-20       Impact factor: 10.122

Review 4.  Cancer and comorbidity: The role of leptin in breast cancer and associated pathologies.

Authors:  Amitabha Ray
Journal:  World J Clin Cases       Date:  2018-10-26       Impact factor: 1.337

5.  Association of Serum Paraoxonase 1 Activities, Polymorphisms and Oxidative Stress in Breast Cancer Patients with Type 2 Diabetes Mellitus.

Authors:  Fatma Ceyla Eraldemir; Nihal Üren; Tuğba Kum; Burcu Erbay; Deniz Şahin; Emel Ergül; Esra Acar; Doğa Özsoy; Mustafa Çekmen; Hale Kır; Zafer Utkan
Journal:  J Med Biochem       Date:  2019-05-11       Impact factor: 3.402

6.  The association between diabetes and thyroid cancer risk: a hospital-based case-control study in China.

Authors:  Meng Wang; Wei-Wei Gong; Feng Lu; Ru-Ying Hu; Qing-Fang He; Min Yu
Journal:  BMC Endocr Disord       Date:  2021-01-28       Impact factor: 2.763

7.  Diabetes and risk of cancer incidence: results from a population-based cohort study in northern Italy.

Authors:  Paola Ballotari; Massimo Vicentini; Valeria Manicardi; Marco Gallo; Sofia Chiatamone Ranieri; Marina Greci; Paolo Giorgi Rossi
Journal:  BMC Cancer       Date:  2017-10-25       Impact factor: 4.430

8.  Type 2 diabetes mellitus does not increase the risk of multiple myeloma: a systematic review and meta-analysis.

Authors:  Chenlu Zhang; Yuou Sha; Haiyan Liu; Dan Guo; Yijing Jiang; Lemin Hong; Lili Shi; Hongming Huang
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.